• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lumos Pharma Inc (NQ: LUMO )

    3.810 -0.140 (-3.54%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 65,686
    Open 3.990
    Bid (Size) 3.200 (1)
    Ask (Size) 4.150 (4)
    Prev. Close 3.950
    Today's Range 3.710 - 4.000
    52wk Range 1.370 - 4.550
    Shares Outstanding 8,357,391
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
    From Lumos Pharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +18.32%
    +18.32%
    1 Month
    +97.41%
    +97.41%
    3 Month
    +51.79%
    +51.79%
    6 Month
    +25.74%
    +25.74%
    1 Year
    +12.72%
    +12.72%

    More News

    Read More
    Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma: Q4 Earnings Insights
    Via Benzinga
    Earnings Preview: Lumos Pharma
    Via Benzinga
    Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
    Via InvestorPlace
    Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 7, 2024
    Via Benzinga
    Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?
    Via Benzinga
    Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.